Among 5,043 invasive pneumococcal disease (IPD) isolates identified through South African national surveillance from 2003 to 2007, we estimated the effect of trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis on antimicrobial resistance. Patients on TMP-SMX prophylaxis were more likely to have a pneumococcal isolate nonsusceptible to TMP-SMX, penicillin, and rifampin. TMP-SMX nonsusceptibility was associated with nonsusceptibility to penicillin, erythromycin, and rifampin and multidrug resistance. This study informs empirical treatment of suspected IPD in patients with a history of TMP-SMX use.
I n South Africa, as well as globally, many patients with documented or suspected HIV infection are given trimethoprimsulfamethoxazole (TMP-SMX) prophylaxis to prevent opportunistic infections and subsequent mortality (1, 3) . Therefore, this preventative therapy is both important and common in South Africa, where an estimated 11% of the population is living with HIV/AIDS (13) . Depending on the region and subpopulation, the prevalence of TMP-SMX prophylaxis use in South Africa ranges from around 30% to 70% (4, 7, 12, 14) . TMP-SMX prophylaxis can lead to antimicrobial resistance in organisms such as Streptococcus pneumoniae (8, 9, 10) . Additionally, due to mechanisms of linked resistance, TMP-SMX exposure may demonstrate associations with resistance to antimicrobials besides TMP-SMX (2, 5, 10, 11) .
This study investigates the association between TMP-SMX prophylaxis and antibiotic nonsusceptibility by examining laboratory-confirmed cases of invasive pneumococcal disease (IPD) reported to the South African national surveillance system from 2003 through 2007. In addition, the association between TMP-SMX nonsusceptibility and nonsusceptibility to other antibiotics was explored in an effort to quantify the effect of linked resistance.
Isolates and demographic data sent from 120 clinical microbiology laboratories to the National Institute for Communicable Diseases (NICD) from January 2003 through December 2007 were analyzed. Additionally, expanded clinical and demographic information on patients at 16 enhanced surveillance sites in all nine provinces was collected. A case of IPD was defined as isolation of S. pneumoniae from any normally sterile site that is culture positive or latex antigen test positive with supporting evidence (consistent Gram stain or PCR positive). Cases eligible for inclusion in the analysis met the following criteria: (i) from an enhanced site, as history of TMP-SMX prophylaxis was collected only at enhanced sites; (ii) have a viable isolate with susceptibility results; (iii) have a completed demographic and clinical report; (iv) have a known TMP-SMX prophylaxis status. A total of 5,043 IPD cases were included, of which 1,057 were receiving TMP-SMX prophylaxis and 3,986 were not (see Fig. S1 in the supplemental material). Among those on prophylaxis, 96% were HIV seropositive, and the duration of prophylaxis prior to IPD speci-men collection had a mean of 322 days (range, 1 to 2,677 days; interquartile range [IQR], 75 to 420 days).
TMP-SMX nonsusceptibility was more common among patients on prophylaxis (84% versus 54%; adjusted odds ratio [aOR] ϭ 2.54, 95% confidence interval [CI] ϭ 2.02 to 3.19) (Table 1). A significant association was also evident between TMP-SMX prophylaxis and both penicillin (aOR ϭ 1.71, 95% CI ϭ 1.39 to 2.07) and rifampin (aOR ϭ 1.76, 95% CI ϭ 1.28 to 2.43) nonsusceptibility ( Table 2) . A total of 49% of those on TMP-SMX prophylaxis exhibited nonsusceptibility to penicillin (versus 30% of those not on prophylaxis), and 11% of those on prophylaxis were nonsusceptible to rifampin, compared to 3% of those not on prophylaxis. Though 22% of patients on prophylaxis exhibited nonsusceptibility to erythromycin (versus 12% of those not on prophylaxis) and 27% of those on prophylaxis had multidrug nonsusceptibility (versus 16%), prophylaxis was only a significant predictor of erythromycin and multidrug nonsusceptibility in the univariate analyses, not in the multivariable models.
TMP-SMX-nonsusceptible isolates were 23.29 (95% CI ϭ 17.84 to 30.41) times as likely to be nonsusceptible to penicillin and 6.68 (95% CI ϭ 4.65 to 9.60) times as likely to be nonsusceptible to erythromycin (Table 3) . TMP-SMX nonsusceptibility also was a predictor of rifampin nonsusceptibility (aOR ϭ 2.58, 95% CI ϭ 1.71 to 3.91) and multidrug resistance (aOR ϭ 29.71, 95% CI ϭ 17.86 to 49.40).
All of the previously described associations were also explored in HIV-seropositive patients exclusively, to see if this subpopulation had any differing risk factors or resulting associations with Fig. S1 in the supplemental material) and that were not missing any of the variables of interest were included in the tables of univariate and multivariable results. TMP-SMX, trimethoprim-sulfamethoxazole; IPD, invasive pneumococcal disease; OR, odds ratio; CI, confidence interval; PCV, pneumococcal conjugate vaccine; *, statistically significant OR (P value of Ͻ0.01). b Odds ratio is also adjusted for South African province. c Defined as a specimen collection date Ն2 days after patient admission date.
antibiotic nonsusceptibilities. The model results in HIVseropositive IPD cases only (not presented) were strikingly similar to those in all patients, and the relationships between the predictors and the nonsusceptibility outcomes remain consistent. The only notable difference was that the effect of TMP-SMX prophylaxis on rifampin nonsusceptibility was not as pronounced (aOR ϭ 1.41, 95% CI ϭ 0.97 to 2.03).
Among all individuals, regardless of HIV status, TMP-SMX prophylaxis was a risk factor for having a TMP-SMXnonsusceptible pneumococcal infection. These findings are consistent with previously reported findings that TMP-SMX use leads to pneumococcal resistance to the drug itself (5, 8, 10) , and we found a similar measure of effect for the association between TMP-SMX prophylaxis and TMP-SMX nonsusceptibility as that previously shown by Madhi et al. (10) .
In addition, we found significant associations between prophylaxis and nonsusceptibility to penicillin and rifampin. Penicillin resistance is of particular concern, as severe bacterial infections in Africa are often still treated with penicillin, and the use of TMP-SMX in this area will likely increase as more HIV-infected individuals are put on prophylaxis to prevent opportunistic infections.
These results provide evidence of linked resistance in the pneumococcus and indicate that TMP-SMX nonsusceptibility is a strong driver of multidrug resistance, given that 98% of all multidrug-nonsusceptible isolates in this study were nonsusceptible to TMP-SMX. This contrasts a recent study from the United States, where TMP-SMX prophylaxis is not as widely used, which reports half the amount of TMP-SMX resistance we observed in South Africa (6) .
In summary, TMP-SMX prophylaxis is associated with an in- Fig. S1 in the supplemental material) and that were not missing any of the variables of interest were included in each of the models (penicillin, n ϭ 5,039; erythromycin, n ϭ 5,039; rifampin, n ϭ 4,855; multiple drug resistance, n ϭ 4,855). TMP-SMX, trimethoprimsulfamethoxazole; OR, odds ratio; CI, confidence interval; *, all P values are Ͻ0.0001. b Adjusted OR is adjusted for age, serotype, province, and specimen collection year. c Adjusted OR is adjusted for nosocomial infection, tuberculosis treatment, serotype, province, and specimen collection year. crease in TMP-SMX, penicillin, and rifampin nonsusceptibility in the pneumococcus. This is valuable information as we continue to assess the risks and benefits of TMP-SMX prophylaxis. This study also helps inform empirical treatment of suspected IPD in patients with a history of TMP-SMX use.
